reports
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Arjo AB: 1 director
A director at Arjo AB bought 100,000 shares at 32.750SEK and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Bonesupport Holding AB: 1 director
A director at Bonesupport Holding AB bought 2,000 shares at 273.000SEK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 Sep...
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025 The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day.The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session.The purpose of the event is to give institutional investors and financial analysts an introductio...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Small Cap Research
- Karl Bokvist
AF B AF POYRY AB CLASS B
INDT INDUTRADE AB
RATO B RATOS AB CLASS B
VIT B VITEC SOFTWARE GROUP AB
HPOL B HEXPOL AB CLASS B
ADDV A ADDVISE GROUP
MCAP MEDCAP
A2DRL9 SDIPTECH AB B
BHG BHG GROUP
ADDT B ADDTECH AB CLASS B
LAGR B LAGERCRANTZ GROUP AB SERIES B
SWEC B SWECO AB CLASS B
SF STILLFRONT GROUP AB
SINCH SINCH AB
VIMIAN VIMIAN GROUP AB
BEIJ B BEIJER REF AB
LIFCO B LIFCO AB
NIBE B NIBE INDUSTRIER AB
INSTAL INSTALCO AB
HTRO HEXATRONIC GROUP AB
ANOD B ADDNODE GROUP AKTIEBOLAG (PUBL)
VESTUM VESTUM AB
EMBRAC B EMBRACER GROUP AB
GREEN GREEN LANDSCAPING GROUP AB (PUBL)
- ABGSC Healthcare Research
- Sten Gustafsson
Ambu AS: 1 director
A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
MedCap AB: 2 directors
A director at MedCap AB sold 50,000 shares at 444.000SEK and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
Coloplast AS: 1 director
A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Geir Hiller Holom
PhotoCure (Buy, TP: NOK80.00) - Generally in line
Photocure reported c7% YOY product revenue growth for Q1, but operating expenses rose substantially, resulting in EBIT of NOK-5.6m, down YOY from NOK0.7m in Q1 2024. The company reiterated its guidance for 2025. A webcast is scheduled for today at 14:00 CET.
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
- ABGSC Healthcare Research
- Morten Larsen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.